219 related articles for article (PubMed ID: 26352582)
1. Novel therapeutic targets in multiple myeloma.
Cottini F; Anderson K
Clin Adv Hematol Oncol; 2015 Apr; 13(4):236-48. PubMed ID: 26352582
[TBL] [Abstract][Full Text] [Related]
2. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
3. New insights into therapeutic targets in myeloma.
Anderson KC
Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma.
Mitsiades CS; Chen-Kiang S
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S5-13. PubMed ID: 23806982
[TBL] [Abstract][Full Text] [Related]
7. The next generation of novel therapies for the management of relapsed multiple myeloma.
Gonsalves WI; Milani P; Derudas D; Buadi FK
Future Oncol; 2017 Jan; 13(1):63-75. PubMed ID: 27513456
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic strategies for multiple myeloma.
Mimura N; Hideshima T; Anderson KC
Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
[TBL] [Abstract][Full Text] [Related]
9. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
Anreddy N; Hazlehurst LA
J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
12. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
Terpos E; Dimopoulos MA; Sezer O
Leukemia; 2007 Sep; 21(9):1875-84. PubMed ID: 17611556
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies for the treatment of multiple myeloma.
Saini N; Mahindra A
Discov Med; 2013 Apr; 15(83):251-8. PubMed ID: 23636142
[TBL] [Abstract][Full Text] [Related]
14. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
15. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
Bianchi G; Anderson KC
CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
[TBL] [Abstract][Full Text] [Related]
16. Novel targeted agents in the treatment of multiple myeloma.
Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
[TBL] [Abstract][Full Text] [Related]
17. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.
Siegel DS
Semin Hematol; 2012 Jul; 49 Suppl 1():S3-15. PubMed ID: 22727390
[TBL] [Abstract][Full Text] [Related]
18. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
19. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy of multiple myeloma.
Kyle RA
Hematology; 2012 Apr; 17 Suppl 1():S125-8. PubMed ID: 22507799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
